{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses that a-synuclein is involved in neurodegenerative diseases and its role in PLD2 inhibition.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as related to PLD2 inhibition."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays measuring PLD2 inhibition are relevant to the described disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The assays reflect the disease pathogenesis."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly mention controls or replicates, but the assay is standard.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted in the field."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "A30P shows similar inhibition to wild-type, supporting a pathogenic role through PLD2 activity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses that a-synuclein is involved in neurodegenerative diseases and its role in PLD2 inhibition.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as related to PLD2 inhibition."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays measuring PLD2 inhibition are relevant to the described disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The assays reflect the disease pathogenesis."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly mention controls or replicates, but the assay is standard.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted in the field."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "A53T shows enhanced inhibition compared to wild-type, supporting a pathogenic role through increased PLD2 activity."
    }
  ]
}